HIGHLIGHTS
- Who: Filippos Triposkiadis and collaborators from the School of Medicine, European University Cyprus, Nicosia, Cyprus have published the article: Amyloids and the Heart: An Update, in the Journal: (JOURNAL)
- Future: And Future Investigations Promising diagnostic and therapeutic modalities are currently available for patients with cardiac amyloidosis.
SUMMARY
The two most prevalent systemic amyloidosis types affecting the heart in the vast majority (>95%) of cases are immunoglobulin light chain (AL) amyloidosis and transthyretin (TTR) amyloidosis (ATTR amyloidosis). The diagnosis of amyloidosis and specifically of cardiac involvement is often fortuitous on imaging or . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.